Liquid biopsy might be extremely helpful in understanding or characterizing specific cancer information in real-time fashion, using a simple blood draw, but still is under development for routine clinical use.[29] Second, the planned number of patients enrolled in this trial is 38, which may be adequate to explore efficacy in HER2-amplified solid tumors. Here, ERBB2 is linked to cancer.